Natriuretic Peptides as a Prognostic and Risk Stratification Tool in Assessment of Valvular Heart Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05439369

Enrollment

Registered

2022-06-30

Start date

2022-08-01

Completion date

2023-01-01

Last updated

2022-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Valvular Heart Disease Stenosis and Regurgitation

Brief summary

NPs can be used To detect subset of asymptomatic with subtle LV dysfunction for further evaluation and earlier referral for intervention and its correlation with echocardiographic finding.

Detailed description

Each patient included in the study will undergo: 1. History taking: Analysis of patient symptoms and signs (dyspnea , orthopnea , Paroxysmal nocturnal dyspnea, lower limb edema , tachypalpitations,…etc ) 2. Clinical examination: * Detecion of each patient body weight , height , calculation of BMI. * General examination for detection of signs of Heart failure (raised JVP , lower limb edema, ..etc) * Examination to respiratory system * Auscultation of the heart for detection of valvular affection before echocardiography Invesigations: Laboratory investigations: Urea and creatinine . b) ECG : for exclusion of atrial fibrillation and other arrythmias. 2D Transthorathic Echocardiography (TTE) Evaluation of valve morphology and thickness , gradients and valve area , regurgitant lesions and its severity. Evaluation of internal cardiac dimensions and function. 5- Natriuretic peptides: as a useful screening tool to differentiate symptomatic and asymptomatic patients.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* All patients echocardiographically diagnosed with significant valve lesions. Rheumatic Heart disease with significant but asymptomatic valvular Heart Disease especially (Mitral valve disease )(MS and MR) Gender: male & female

Exclusion criteria

* Cases with increased level of BNP as in : Renal impairment Advanced age and obesity Atrial fibrillation and acute coronary syndromes Prior lung diseases and acute illness

Design outcomes

Primary

Measure	Time frame	Description
early detection of subclinical LV dysfunction.	1 year	early detection of subclinical LV dysfunction.

Countries

Egypt

Contacts

Primary ContactMuhammad KE thabet, resident

muhammadkhidr147@gmail.com01150713889

Backup ContactAmr Ahmed Aly Yousif, Professor

Amryoussef111@yahoo.com01027355511

Outcome results